Skip to main content Accessibility help

Carbapenem-Resistant Klebsiella pneumoniae in Post-Acute-Care Facilities in Israel



To assess the prevalence of and risk factors for carbapenem-resistant Klebsiella pneumoniae (CRKP) carriage among patients in post-acute-care facilities (PACFs) in Israel.

Design, Setting, and Patients.

A cross-sectional prevalence survey was conducted in 12 PACFs. Rectal swab samples were obtained from 1,144 patients in 33 wards. Risk factors for CRKP carriage were assessed among the cohort. Next, a nested, matched case-control study was conducted to define individual risk factors for colonization. Finally, the cohort of patients with a history of CRKP carriage was characterized to determine risk factors for continuous carriage.


The prevalence of rectal carriage of CRKP among 1,004 patients without a history of CRKP carriage was 12.0%. Independent risk factors for CRKP carriage were prolonged length of stay (odds ratio [OR], 1.001; P < .001), sharing a room with a known carrier (OR, 3.09; P = .02), and increased prevalence of known carriers on the ward (OR, 1.02; P = .013). A policy of screening for carriage on admission was protective (OR, 0.41; P = .03). Risk factors identified in the nested case-control study were antibiotic exposure during the prior 3 months (OR, 1.66; P = .03) and colonization with other resistant pathogens (OR, 1.64; P = .03). Among 140 patients with a history of CRKP carriage, 47% were colonized. Independent risk factors for continued CRKP carriage were antibiotic exposure during the prior 3 months (OR, 3.05; P = .04), receipt of amoxicillin-clavulanate (OR, 4.18; P = .007), and screening within 90 days of the first culture growing CRKP (OR, 2.9; P = .012).


We found a large reservoir of CRKP in PACFs. Infection-control polices and antibiotic exposure were associated with patient colonization.


Corresponding author

National Center for Infection Control, 6 Weizmann Street, Tel Aviv 64239, Israel (


Hide All
1.Dennesen, PJ, Bonten, MI, Weinstein, RA. Multiresistant bacteria as a hospital epidemic problem. Ann Med 1998;30:176185.
2.Lautenbach, E, Marsicano, R, Tolomeo, P, Heard, M, Serrano, S, Stieritz, DD. Epidemiology of antimicrobial resistance among gram-negative organisms recovered from patients in a multistate network of long-term care facilities. Infect Control Hosp Epidemiol 2009;30:790793.
3.Trick, WE, Weinstein, RA, DeMarais, PL, et al.Colonization of skilled-care facility residents with antimicrobial-resistant pathogens. J Am Geriatr Soc 2001;49:270276.
4.Wiener, J, Quinn, JP, Bradford, PA, et al.Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999;281:517523.
5.Muder, RR, Brennen, C, Wagener, MM, et al.Methicillin-resistant staphylococcal colonization and infection in a long-term care facility. Ann Intern Med 1991;114:107112.
6.Muto, CA, Jernigan, JA, Ostrowsky, BE, et al.SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 2003;24:362386.
7.Centers for Disease Control and Prevention. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep 2009;58:256260.
8.Trick, WE, Weinstein, RA, DeMarais, PL, et al.Comparison of routine glove use and contact-isolation precautions to prevent transmission of multidrug-resistant bacteria in a long-term care facility. J Am Geriatr Soc 2004;52:20032009.
9.Bradford, PA, Bratu, S, Urban, C, et al.Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lacta-mases in New York City. Clin Infect Dis 2004;39:5560.
10.Bratu, S, Brooks, S, Burney, S, et al.Detection and spread of Escherichia colt possessing the plasmid-borne carbapenemase KPC-2 in Brooklyn, New York. Clin Infect Dis 2007;44:972975.
11.Cuzon, G, Naas, T, Demachy, MC, Nordmann, P. Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in Klebsiella pneumoniae isolate from Greece. Antimicrob Agents Chemother 2008;52:796797.
12.Cai, JC, Zhou, HW, Zhang, R, Chen, GX. Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital. Antimicrob Agents Chemother 2008;52:20142018.
13.Hidron, AI, Edwards, JR, Patel, J, et al.NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008;29:9961011.
14.Patel, G, Huprikar, S, Factor, SH, Jenkins, SG, Calfee, DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29:10991106.
15.Schwaber, MJ, Klarfeld-Lidji, S, Navon-Venezia, S, Schwartz, D, Leavitt, A, Carmeli, Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008;52:10281033.
16.Borer, A, Saidel-Odes, L, Riesenberg, K, et al.Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 2009;30:972976.
17.Schwaber, MJ, Carmeli, Y. Carbapenem-resistant Enterobacteriaceae. a potential threat. JAMA 2008;300:29112913.
18.Schwaber, MJ, Carmeli, Y. Don't forget the bacterial threat. Wall Street Journal. 12 August 2009.
19.Leavitt, A, Navon-Venezia, S, Chmelnitsky, I, Schwaber, MJ, Carmeli, Y. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother 2007;51:30263029.
20.Samra, Z, Ofir, O, Lishtzinsky, Y, Madar-Shapiro, L, Bishara, J. Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel. Int J Antimicrob Agents 2007;30:525529.
21.Hussein, K, Sprecher, H, Mashiach, T, Oren, I, Kassis, I, Finkelstein, R. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol 2009;30:666671.
22.Schwaber, MJ, Lev, B, Israeli, A, et al.Containment of a countrywide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis 2011;52:848855.
23.Charlson, ME, Pompei, P, Ales, KL, MacKenzie, CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373383.
24.Goldstone, LA, Goldstone, J. The Norton score: an early warning of pressure sores? J Adv Nurs 1982;7:419426.
25.Samra, Z, Bahar, J, Madar-Shapiro, L, Aziz, N, Israel, S, Bishara, J. Evaluation of CHROMagar KPC for rapid detection of carbapenem-resistant Enterobacteriaceae. J Clin Microbiol 2008;46:310311.
26.Schechner, V, Straus-Robinson, K, Schwartz, D, et al.Evaluation of PCR-based testing for surveillance of KPC-producing carbapenem-resistant members of the Enterobacteriaceae family. J Clin Microbiol 2009;47:32613265.
27.Clancy, M, Graepler, A, Wilson, M, Douglas, I, Johnson, J, Price, CS. Active screening in high-risk units is an effective and cost-avoidant method to reduce the rate of methicillin-resistant Staphylococcus aureus infection in the hospital. Infect Control Hosp Epidemiol 2006;27:10091017.
28.Morris-Downes, M, Smyth, EG, Moore, J, et al.Surveillance and endemic vancomycin-resistant enterococci: some success in control is possible. J Hosp Infect 2010;75:228233.
29.Endimiani, A, Depasquale, JM, Forero, S, et al.Emergence of blaKPC-containing Klebsiella pneumoniae in a long-term acute care hospital: a new challenge to our healthcare system. J Antimicrob Chemother 2009;64:11021110.
30.Richards, CL Jr., Darradji, M, Weinberg, A, Ouslander, JG. Antimicrobial use in post-acute care: a retrospective descriptive analysis in seven long-term care facilities in Georgia. J Am Med Dir Assoc 2005;6:109112.
31.Nicolle, LE. Infection control in long-term care facilities. Clin Infect Dis 2000;31:752756.
32.High, KP, Bradley, SF, Gravenstein, S, et al.Clinical practice guideline for the evaluation of fever and infection in older adult residents of long-term care facilities: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2009,48:149171.
33.Pacio, GA, Visintainer, P, Maguire, G, Wormser, GP, Raffalli, J, Montecalvo, MA. Natural history of colonization with vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and resistant gram-negative bacilli among long-term-care facility. Infect Control Hosp Epidemiol 2003;24:238241.
34.Perez, F, Endimiani, A, Ray, AJ, et al.Carbapenem-resistant Aci-netobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. J Antimicrob Chemother 2010;65:18071818.
35.Ostrowsky, BE, Trick, WE, Sohn, AH, et al.Control of vancomycin-resistant enterococcus in health care facilities in a region. N Engl J Med 2001;344:14271433.


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed